About Arylsulfatase A
Arylsulfatase A (ARSA) is a protein
from Homo sapiens identified by UniProt accession
P15289, 507 residues long.
MolForge cross-references it against 0 known binders and
200 disease associations.
Target properties
| Protein name | Arylsulfatase A |
| UniProt accession | P15289 |
| Gene | ARSA |
| Organism | Homo sapiens |
| Length | 507 residues |
| Molecular weight | — |
| EC numbers | — |
| Target class | UNCLASSIFIED |
| Subcellular location | — |
| Keywords | — |
Druggability
Target tractability assessment (Open Targets + pocket analysis). No approved drug
| Druggability tier | MEDIUM |
| Druggability score | — |
| Pocket score | — |
| Max clinical phase | — |
Disease associations (200)
Diseases linked to this target (Open Targets).
- metachromatic leukodystrophy, juvenile form · score 0.82
- metachromatic leukodystrophy · score 0.82
- metachromatic leukodystrophy, adult form · score 0.60
- metachromatic leukodystrophy, late infantile form · score 0.59
- genetic disorder · score 0.52
- Neurodevelopmental disorder · score 0.41
- Multiple sulfatase deficiency · score 0.37
- mucosulfatidosis · score 0.37
- Dystonia · score 0.37
- leukodystrophy · score 0.34
3D Structure (1)
Experimental (PDB) and predicted (AlphaFold) structures for this protein.
| Structure | Source | Method | Mean pLDDT | Resolution (Å) |
| AF-P15289-F1 | alphafold | PREDICTED | 96.11 | — |
Amino-acid sequence (507 residues)
MGAPRSLLLA LAAGLAVARP PNIVLIFADD LGYGDLGCYG HPSSTTPNLD QLAAGGLRFT DFYVPVSLCT PSRAALLTGR LPVRMGMYPG VLVPSSRGGL PLEEVTVAEV LAARGYLTGM AGKWHLGVGP EGAFLPPHQG FHRFLGIPYS HDQGPCQNLT CFPPATPCDG GCDQGLVPIP LLANLSVEAQ PPWLPGLEAR YMAFAHDLMA DAQRQDRPFF LYYASHHTHY PQFSGQSFAE RSGRGPFGDS LMELDAAVGT LMTAIGDLGL LEETLVIFTA DNGPETMRMS RGGCSGLLRC GKGTTYEGGV REPALAFWPG HIAPGVTHEL ASSLDLLPTL AALAGAPLPN VTLDGFDLSP LLLGTGKSPR QSLFFYPSYP DEVRGVFAVR TGKYKAHFFT QGSAHSDTTA DPACHASSSL TAHEPPLLYD LSKDPGENYN LLGGVAGATP EVLQALKQLQ LLKAQLDAAV TFGPSQVARG EDPALQICCH PGCTPRPACC HCPDPHA
Explore Arylsulfatase A with MolForge
Find binders, run structure-based screening, and map this target across
diseases and approved drugs with our AI-powered platform.
Browse all targets